MetaVia

#Drug discovery #GLP-1 #MetaVia #Obesity

What will define the winners in a crowded GLP-1 era? 

HH Kim, CEO and President of MetaVia, asks what the next generation of GLP-1 drugs might look like.  Over the past two decades, only a few biotech sectors have experienced a hype cycle as rapid and publicly frenzied as the obesity drug sector. In just over a year, GLP-1s… Read More

#Exclusive Content

Weight loss concept
#GLP-1 #Metabolic diseases #MetaVia #Obesity #Phase I trial #Weight loss

Statistically significant PhI results for GLP-1/glucagon dual agonist

MetaVia has announced positive statistically significant results from the eight-week, non-titrated 48mg, multiple ascending dose (MAD) cohort of its Phase I clinical trial of DA-1726.  DA-1726 is a novel, dual oxyntomodulin (OXM) analogue agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for… Read More

#News

Human liver
#Liver disease #MetaVia #Type 2 diabetes

Novel GPR119 agonist shows promise in MASH and diabetes

MetaVia has announced that data from its Phase IIa clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH), demonstrates both hepatoprotective and glucose-regulating effects. The data was presented in a late-breaking poster presentation at the European Association for the Study… Read More

#News

Obese man measures his waist
#GLP-1 #MetaVia #Obesity #Phase I trial #Weight loss

New obesity drug shows superior tolerability to GLP-1 agonists

MetaVia has announced positive results from the four-week multiple ascending dose (MAD) Part 2 of its Phase I clinical trial of DA-1726 for the treatment of obesity.  DA-1726 is a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor… Read More

#Editor's Choice #News